Recommended Vaccinations for Adults: What Respirologists Need to Know
DOI:
https://doi.org/10.58931/cret.2025.115Abstract
Patients with underlying respiratory comorbidities such as chronic obstructive pulmonary disease (COPD) are at greater risk of severe manifestations of the following vaccine-preventable diseases: COVID-19, influenza, herpes zoster, pertussis, pneumococcal disease, and respiratory syncytial virus (RSV). The following case illustrates how respirologists can recommend and support important patient vaccination updates.
References
Adult national immunization coverage survey (aNICS): 2023 results. Government of Canada. [updated 2024 Jan 17, cited 2025 Feb 6]. Available from: https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/adult-national-immunization-coverage-survey-2023-results.html
Summary of NACI statement of January 10, 2025: Guidance on the use of COVID-19 vaccines for 2025 to summer 2026. Government of Canada. [updated 2025 Jan 21, cited 2025 Feb 6]. Available from: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-guidance-covid-19-vaccines-2025-summer-2026.html
COVID-19 signs, symptoms and severity of disease: a clinical guide. Government of Canada. [updated 2022 Jun 22, cited 2025 Feb 6]. Available from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html
Statement on seasonal influenza vaccine for 2024-2025. Government of Canada. [updated 2024 Aug 14, cited 2025 Feb 6]. Available from: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-seasonal-influenza-vaccine-2024-2025.html
2018 NACI update on herpes zoster vaccines. Government of Canada. [updated 2019 Mar 28, cited 2025 Feb 6]. Available from: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2018-44/issue-9-september-6-2018/article-6-2018-naci-update-herpes-zoster-vaccines.html
Gabutti G, Valente N, Kuhdari P, Lupi S, Stefanati A. Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine. J Med Microbiol. 2016;65(12):1363-1369. doi: 10.1099/jmm.0.000386
Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005. doi: 10.1093/ofid/ofaa005
Macina D, Evans KE. Pertussis in individuals with co-morbidities: a systematic review. Infect Dis Ther. 2021;10(3):1141-1170. doi: 10.1007/s40121-021-00465-z
Summary of NACI statement of November 15, 2024: recommendations on the use of pneumococcal vaccine in adults, including PNEU-C-21. Government of Canada. [updated 2025 Jan 23, cited 2025 Feb 6]. Available from: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-recommendations-use-pneumococcal-vaccines-adults-pneu-c-21.html
Begley KM, Leis, AM, Petrie JG, Truscon R, Johnson E, McSpadden E, et al. Epidemiology of RSV-A and RSV-B in adults and children with medically-attended acute respiratory illness over three seasons. medRxiv. Posted 2022 November 10. doi: https://doi.org/10.1101/2022.11.04.22281968
Statement on the prevention of respiratory syncytial virus disease in older adults. Government of Canada. [updated 2024 Aug 9, cited 2025 Feb 6]. Available from: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-prevention-rsv-disease-older-adults.html
Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults including the expanded used of RSVPreF3 for individuals 50-59 years of age and the use of the new mRNA-1345 vaccine. Government of Canada. [updated 2025 March 9, cited 2025 May 6]. Available from: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-updated-guidance-rsv-vaccines-older-adults-including-expanded-use-rsvpref3-individuals-50-59-years-age-use-new-mrna-1345-vaccine.html
Jacobson RM, St Sauver JL, Griffin JM, MacLaughlin KL, Finney Rutten LJ. How health care providers should address vaccine hesitancy in the clinical setting: evidence for presumptive language in making a strong recommendation. Hum Vaccin Immunother. 2020;16(9):2131-2135. doi: 10.1080/21645515.2020.1735226.
Steben M, Durand N, Guichon JR, Greenwald ZR, McFaul S, Blake J. A National survey of Canadian adults on HPV: knowledge, attitudes, and barriers to the HPV vaccine. J Obstet Gynaecol Can. 2019;41(8):1125-1133.e6. doi: 10.1016/j.jogc.2019.05.005.
